Author

Max Mahoney-Schaefer

University of Washington

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Anthony AsencioiD· 1 shared Ateeqa NaimiD· 1 shared Bertrand C.W. TanneriD· 1 shared Christian MandryckyiD· 1 shared Farid Moussavi‐HaramiiD· 1 shared Galina V. FlintiD· 1 shared Jing ZhaoiD· 1 shared Kristina Bezold KooikeriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiophysics

Anthony AsencioORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Myosin modulator Aficamten inhibits force in cardiac muscle by altering myosin's biochemical activity without changing thick filament structure

Saffie E. Mohran, Kristina Bezold Kooiker, Ateeqa Naim, Matvey Pilagov, Anthony Asencio, Kyrah L. Turner, Weikang Ma, Galina V. Flint, Siyao Jiang, Jing Zhao, Timothy S. McMillen, Christian Mandrycky, Max Mahoney-Schaefer, Thomas C. Irving, Bertrand C.W. Tanner, , Farid Moussavi‐Harami

This paper shows Aficamten inhibits cardiac myosin ATPase without changing thick filament structure, unlike Mavacamten, leading to similar force reduction but different kinetic effects.

bioRxiv · May 14, 2025 · PreprintBiophysics